Drug Profile
Tirapazamine - Teclison
Alternative Names: NSC 130181; SR 259075; SR 4233; TATE; TEC-001; Tirazone; WIN 59075Latest Information Update: 02 Jun 2023
Price :
$50
*
At a glance
- Originator SRI International; Stanford Cancer Institute
- Developer Merck Sharp & Dohme Corp.; SRI International; Teclison
- Class Antineoplastics; Radiation-sensitising agents; Reducing agents; Small molecules; Triazines
- Mechanism of Action Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Cervical cancer
- Phase II Colorectal cancer; Liver cancer; Non-small cell lung cancer
- Discontinued Glioma; Head and neck cancer; Malignant melanoma
Most Recent Events
- 14 Apr 2023 Pharmacodynamics data from the preclinical studies in cancer presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)
- 04 Nov 2022 Teclison suspends phase II trial in hepatocellular carcinoma in USA (NCT03145558)
- 07 Jul 2022 Tirapazamine is still in phase I trials for Liver cancer in the USA (NCT02174549)